Abstract
For the last couple of years, novel coronavirus or SAR-CoV-2 is a severe threat to the world. This new strain of coronavirus emerged on 14th December 2020 and has been infecting many parts of the population around the world to date. These viral spikes will bind with the angiotensin-converting enzymes. Many clinical studies conducted have highlighted the association between cardiovascular diseases and COVID-19. It increases the mortality rate, the risk of injury in myocardial, acute coronary syndromes and thromboembolism. COVID-19 has produced some risk factors such as age and gender as well as comorbidities. Coronavirus may pose several challenges for oncology patients. Among cancer patients, severe respiratory and systemic infection are evident specifically among immunosuppressed and ageing patients. Cancer is said to worsen due to COVID-19 as it is linked with inflammatory burst and lymphopenia. This study has discussed the risk factors in COVID-19 transmission, factors that can aggravate it and clinical interactions between the cardiovascular system. Furthermore, several drugs that have been administered against the virus are believed to affect the patients.